0001209191-21-016983.txt : 20210303
0001209191-21-016983.hdr.sgml : 20210303
20210303170328
ACCESSION NUMBER: 0001209191-21-016983
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210301
FILED AS OF DATE: 20210303
DATE AS OF CHANGE: 20210303
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Konidaris Tasos
CENTRAL INDEX KEY: 0001320982
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38485
FILM NUMBER: 21710166
MAIL ADDRESS:
STREET 1: 103 JFK PARKWAY
CITY: SHORT HILLS
STATE: NJ
ZIP: 07078
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Amneal Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001723128
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
BUSINESS PHONE: (908) 947-3120
MAIL ADDRESS:
STREET 1: 400 CROSSING BOULEVARD
STREET 2: 3RD FLOOR
CITY: BRIDGEWATER
STATE: NJ
ZIP: 08807
FORMER COMPANY:
FORMER CONFORMED NAME: Atlas Holdings, Inc.
DATE OF NAME CHANGE: 20171117
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-03-01
0
0001723128
Amneal Pharmaceuticals, Inc.
AMRX
0001320982
Konidaris Tasos
C/O AMNEAL PHARMACEUTICALS, INC.
400 CROSSING BOULEVARD
BRIDGEWATER
NJ
08807
0
1
0
0
Executive Vice President & CFO
Restricted Stock Units
2021-03-01
4
A
0
144788
0.00
A
Class A Common Stock
144788
144788
D
Performance-Based Restricted Stock Units
2021-03-01
4
A
0
289576
0.00
A
Class A Common Stock
289576
289576
D
Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
The restricted stock units vest in four equal annual installments beginning on March 1, 2022.
Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
Represents the maximum number of shares issuable under the performance-based restricted stock units.
50% of the performance-based restricted stock units are earned and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $8 or higher for 60 consecutive calendar days during the three-year performance period. Additional performance-based restricted stock units are earned at higher levels and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $10 (75%), $12 (100%), $14 (125%), $16 (150%), $18 (175%) and $20 (200%), respectively, for 60 consecutive calendar days during the three-year performance period. For average 60-day closing stock prices between $12 and $20 per share, the number of performance-based restricted stock units that become earned will be determined using straight line interpolation. Any earned performance-based restricted stock units vest in full on February 29,2024, the last day of the performance period.
/s/ Meredith Cook, Attorney-in-Fact
2021-03-03